Comprehensive Stock Comparison
Compare DocGo Inc. (DCGO) vs Agios Pharmaceuticals, Inc. (AGIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | AGIO | 48.0% revenue growth vs DCGO's -1.2% |
| Quality / Margins | DCGO | -14.0% net margin vs AGIO's -9.0% |
| Stability / Safety | AGIO | Beta 0.91 vs DCGO's 1.20, lower leverage |
| Dividends | DCGO | 100.0% yield; 1-year raise streak; AGIO pays no meaningful dividend |
| Momentum (1Y) | AGIO | -14.9% vs DCGO's -76.8% |
| Efficiency (ROA) | DCGO | -14.6% ROA vs AGIO's -29.0%, ROIC 7.5% vs -26.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
DocGo is a mobile healthcare and medical transportation provider that brings medical services directly to patients' homes, workplaces, and events. It generates revenue primarily through contracted mobile health services—including COVID-19 testing and on-site event healthcare—and medical transportation services like ambulance and wheelchair transport. The company's competitive advantage lies in its integrated platform that combines transportation with on-site medical care, creating a seamless mobile healthcare delivery system.
Agios Pharmaceuticals is a biopharmaceutical company focused on developing treatments for rare genetic diseases related to cellular metabolism. It generates revenue primarily from sales of its lead drug PYRUKYND for pyruvate kinase deficiency — with additional income from research collaborations and milestone payments — while advancing a pipeline of other metabolic therapies. The company's competitive advantage lies in its deep expertise in cellular metabolism science and proprietary platform for targeting metabolic pathways in rare diseases.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
DCGO leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). AGIO leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Financial Metrics (TTM)
DCGO is the larger business by revenue, generating $368M annually — 8.2x AGIO's $45M. Profitability is closely matched — net margins range from -14.0% (DCGO) to -9.0% (AGIO). On growth, AGIO holds the edge at +43.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | DCGODocGo Inc. | AGIOAgios Pharmaceuti… |
|---|---|---|
| RevenueTrailing 12 months | $368M | $45M |
| EBITDAEarnings before interest/tax | -$66M | -$470M |
| Net IncomeAfter-tax profit | -$52M | -$401M |
| Free Cash FlowCash after capex | $52M | -$414M |
| Gross MarginGross profit ÷ Revenue | +31.2% | +84.4% |
| Operating MarginEBIT ÷ Revenue | -22.0% | -10.6% |
| Net MarginNet income ÷ Revenue | -14.0% | -9.0% |
| FCF MarginFCF ÷ Revenue | +14.1% | -9.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -48.9% | +43.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -6.4% | -111.0% |
Valuation Metrics
| Metric | DCGODocGo Inc. | AGIOAgios Pharmaceuti… |
|---|---|---|
| Market CapShares × price | $73M | $2.25T |
| Enterprise ValueMkt cap + debt − cash | $41M | $2.25T |
| Trailing P/EPrice ÷ TTM EPS | 3.99x | -4.25x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 0.92x | — |
| Price / SalesMarket cap ÷ Revenue | 0.12x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 0.25x | 1.47x |
| Price / FCFMarket cap ÷ FCF | 1.13x | — |
Profitability & Efficiency
DCGO delivers a -19.8% return on equity — every $100 of shareholder capital generates $-20 in annual profit, vs $-31 for AGIO. AGIO carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to DCGO's 0.18x. On the Piotroski fundamental quality scale (0–9), DCGO scores 7/9 vs AGIO's 3/9, reflecting strong financial health.
| Metric | DCGODocGo Inc. | AGIOAgios Pharmaceuti… |
|---|---|---|
| ROE (TTM)Return on equity | -19.8% | -31.2% |
| ROA (TTM)Return on assets | -14.6% | -29.0% |
| ROICReturn on invested capital | +7.5% | -26.6% |
| ROCEReturn on capital employed | +8.8% | -33.8% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 3 |
| Debt / EquityFinancial leverage | 0.18x | 0.03x |
| Net DebtTotal debt minus cash | -$32M | -$49M |
| Cash & Equiv.Liquid assets | $89M | $89M |
| Total DebtShort + long-term debt | $57M | $40M |
| Interest CoverageEBIT ÷ Interest expense | -38.97x | — |
Total Returns (with DRIP)
A $10,000 investment in AGIO five years ago would be worth $6,363 today (with dividends reinvested), compared to $707 for DCGO. Over the past 12 months, AGIO leads with a -14.9% total return vs DCGO's -76.8%. The 3-year compound annual growth rate (CAGR) favors AGIO at 6.1% vs DCGO's -57.2% — a key indicator of consistent wealth creation.
| Metric | DCGODocGo Inc. | AGIOAgios Pharmaceuti… |
|---|---|---|
| YTD ReturnYear-to-date | -19.1% | +11.2% |
| 1-Year ReturnPast 12 months | -76.8% | -14.9% |
| 3-Year ReturnCumulative with dividends | -92.2% | +19.4% |
| 5-Year ReturnCumulative with dividends | -92.9% | -36.4% |
| 10-Year ReturnCumulative with dividends | -93.0% | -21.2% |
| CAGR (3Y)Annualised 3-year return | -57.2% | +6.1% |
Risk & Volatility
AGIO is the less volatile stock with a 0.91 beta — it tends to amplify market swings less than DCGO's 1.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AGIO currently trades 65.7% from its 52-week high vs DCGO's 22.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DCGODocGo Inc. | AGIOAgios Pharmaceuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.20x | 0.91x |
| 52-Week HighHighest price in past year | $3.18 | $46.00 |
| 52-Week LowLowest price in past year | $0.66 | $22.24 |
| % of 52W HighCurrent price vs 52-week peak | +22.6% | +65.7% |
| RSI (14)Momentum oscillator 0–100 | 40.1 | 62.3 |
| Avg Volume (50D)Average daily shares traded | 624K | 948K |
Analyst Outlook
DCGO is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | DCGODocGo Inc. | AGIOAgios Pharmaceuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $41.50 |
| # AnalystsCovering analysts | — | 29 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $11829.54 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +18.8% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Dec 20 | Feb 26 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | 100 | 7.54 | -92.5% |
| Agios Pharmaceutica… (AGIO) | 100 | 63.57 | -36.4% |
Agios Pharmaceutica… (AGIO) returned -36% over 5 years vs DocGo Inc. (DCGO)'s -93%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | $48M | $617M | +1176.5% |
| Agios Pharmaceutica… (AGIO) | $70M | $54M | -22.7% |
Agios Pharmaceuticals, Inc.'s revenue grew from $70M (2016) to $54M (2025) — a -2.8% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | -41.8% | 3.2% | +107.7% |
| Agios Pharmaceutica… (AGIO) | -2.8% | -7.6% | -169.0% |
Agios Pharmaceuticals, Inc.'s net margin went from -3% (2016) to -8% (2025).
Chart 4P/E Ratio History — 4 Years
| Stock | 2021 | 2024 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | 37.4 | 23.6 | -36.9% |
DocGo Inc. has traded in a 21x–86x P/E range over 4 years; current trailing P/E is ~4x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| DocGo Inc. (DCGO) | -0.2 | 0.18 | +190.0% |
| Agios Pharmaceutica… (AGIO) | -5.07 | -7.12 | -40.4% |
Agios Pharmaceuticals, Inc.'s EPS grew from $-5.07 (2016) to $-7.12 (2025).
Chart 6Free Cash Flow — 5 Years
DocGo Inc. generated $65M FCF in 2024 (+850% vs 2021). Agios Pharmaceuticals, Inc. generated $-377M FCF in 2025 (+9% vs 2021).
DCGO vs AGIO: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is DCGO or AGIO a better buy right now?
DocGo Inc. (DCGO) offers the better valuation at 4.0x trailing P/E, making it the more compelling value choice. Analysts rate Agios Pharmaceuticals, Inc. (AGIO) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DCGO or AGIO?
Over the past 5 years, Agios Pharmaceuticals, Inc. (AGIO) delivered a total return of -36.4%, compared to -92.9% for DocGo Inc. (DCGO). A $10,000 investment in AGIO five years ago would be worth approximately $6K today (assuming dividends reinvested). Over 10 years, the gap is even starker: AGIO returned -21.2% versus DCGO's -93.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DCGO or AGIO?
By beta (market sensitivity over 5 years), Agios Pharmaceuticals, Inc. (AGIO) is the lower-risk stock at 0.91β versus DocGo Inc.'s 1.20β — meaning DCGO is approximately 33% more volatile than AGIO relative to the S&P 500. On balance sheet safety, Agios Pharmaceuticals, Inc. (AGIO) carries a lower debt/equity ratio of 3% versus 18% for DocGo Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — DCGO or AGIO?
DocGo Inc. (DCGO) is the more profitable company, earning 3.2% net margin versus -764.0% for Agios Pharmaceuticals, Inc. — meaning it keeps 3.2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DCGO leads at 4.7% versus -873.9% for AGIO. At the gross margin level — before operating expenses — AGIO leads at 88.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — DCGO or AGIO?
In this comparison, DCGO (100.0% yield) pays a dividend. AGIO does not pay a meaningful dividend and should not be held primarily for income.
06Is DCGO or AGIO better for a retirement portfolio?
For long-horizon retirement investors, DocGo Inc. (DCGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.20), 100.0% yield). Both have compounded well over 10 years (DCGO: -93.0%, AGIO: -21.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between DCGO and AGIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: DCGO is a small-cap deep-value stock; AGIO is a mega-cap quality compounder stock. DCGO pays a dividend while AGIO does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.